FLT3 and acute myeloid leukemia: More potent and FLT3-specific second-generation FLT3 inhibitors, such as gilteritinib and quizartinib, were subsequently developed and demonstrated clinical benefits in patients with FLT3 mutation-positive (FLT3mut+) relapsed or refractory (R/R) AML (9–11).